基于纳米颗粒的药物与含有他类药物的常规药物的相对药物动力学评价,用于减轻失脂血症
Jacob Cordina1, Isha Ahmad1, Rohan Nath1
1Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo, NSW, 2007, Australia.
Naunyn-Schmiedeberg's archives of pharmacology
|May 8, 2024
概括
纳米颗粒物药物输送显著增强了治疗失脂血症的他类药物. 这种先进的技术可提高口服生物利用率高达400%,为传统的他类药物治疗提供了一个有前途的替代方案.
科学领域:
- 药理学 药理学是指药理学的学科.
- 生物技术是生物技术.
- 药物输送系统 药物输送系统
背景情况:
- 脱脂血症的特征是血脂水平异常,通常用他类药物进行治疗.
- 虽然他类药物有效降低胆固醇,但由于水溶性较低,其口服生物利用性较差.
- 纳米粒子药物输送提供了一个潜在的解决方案来克服这些局限性.
研究的目的:
- 审查关于基于纳米粒子的他类药物的现有文献.
- 与传统的他类药物相比,评估药物动力学概况和疗效的改善.
- 评估纳米粒子技术在他类药物治疗中的潜力.
主要方法:
- 对纳米粒子他类药物药物治疗研究的文献综述.
- 药物动力学数据的比较分析 (生物可用性,Cmax,Tmax).
- 对治疗疗效和安全性概况的评估.
主要成果:
- 纳米粒子他类药物配方显著改善了口服生物可用性,在某些情况下,比传统的他类药物高出400%.
- 在高血度 (Tmax) 和高血度 (Cmax) 的时间内观察到实质性的增强.
- 在基于纳米粒子的他类药物中,增加了循环时间和减少了分泌率.
结论:
- 纳米粒子技术具有显著的潜力,可以彻底改变治疗失脂症的他类药物治疗.
- 与传统的他类药物相比,这种方法提供了优越的药理动力学特征和有效性,并且与最小的缺点相比.
- 纳米粒子他类药物的进一步开发和大规模应用可能极大地有利于患者和医疗保健系统.
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
652
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
652
01:19Nonlinear Pharmacokinetics: Overview
354
Nonlinear or dose-dependent pharmacokinetics is a phenomenon that occurs when the pharmacokinetic parameters of certain drugs deviate from linear pharmacokinetics at higher doses. These drugs do not follow the expected first-order kinetics, where the rate of drug elimination is directly proportional to the drug concentration. Instead, they exhibit a nonlinear relationship, which can be attributed to several factors.
Nonlinearity can arise due to the saturation of plasma protein-binding or...
Nonlinearity can arise due to the saturation of plasma protein-binding or...
354
00:59Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
60
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
60
01:22Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding
157
When a drug follows nonlinear pharmacokinetics, its bioavailability, the amount of the drug that reaches the systemic circulation, can change with different doses. This is due to the presence of a saturable pathway. The pathway becomes saturated as the drug concentration increases, decreasing the absorption rate. Consequently, the drug's bioavailability may be lower than expected at higher doses.
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
To quantify the extent of bioavailability, pharmacologists often use a parameter called .
157
01:07Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
38
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
38
01:23Factors Affecting Dissolution: Particle Size and Effective Surface Area
818
Dissolution kinetics, an essential aspect of oral drug delivery, is significantly influenced by the drug's particle size. According to the Noyes-Whitney dissolution model, the dissolution rate correlates directly with the drug's surface area. The larger the surface area, the higher the drug's solubility in water, leading to a faster drug dissolution rate. Reducing particle size increases the effective surface area, enhancing the dissolution process. Micronization and nanosizing are...
818